Health-related quality of life among HIV-infected patients initiating treatment in Brazil in the single-tablet regimen era.
Adult
Alkynes
Antiretroviral Therapy, Highly Active
Anxiety
Benzoxazines
/ administration & dosage
Brazil
Cyclopropanes
Depression
Drug Combinations
Female
HIV Infections
/ diagnosis
HIV-1
/ drug effects
Heterocyclic Compounds, 3-Ring
/ administration & dosage
Humans
Male
Middle Aged
Outcome Assessment, Health Care
Oxazines
Piperazines
Pyridones
Quality of Life
Surveys and Questionnaires
Tablets
/ administration & dosage
Antiretroviral therapy
HIV
highly active
patient-reported outcome measures
quality of life
Journal
AIDS care
ISSN: 1360-0451
Titre abrégé: AIDS Care
Pays: England
ID NLM: 8915313
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
pubmed:
8
2
2019
medline:
7
1
2020
entrez:
8
2
2019
Statut:
ppublish
Résumé
Health-related quality of life (HRQoL) is a multidimensional concept involving an individual's self-perception about how a disease or treatment impacts their daily life. In this study, we evaluated the HRQoL and factors associated with this outcome in 366 patients initiating combination Antiretroviral Therapy (cART) in Belo Horizonte, Brazil.We measured HRQoL using the EuroQoL-5D 3 level (EQ-5D) and the HIV instrument of the World Health Organization (WHOQOL-HIV BREF) and identified factors associated with HRQoL using multilevel linear regression. Participants had been on cART treatment a median of 65.5 days at the time the instruments were completed. The median HRQoL of patients on the single-tablet regimen containing efavirenz/ tenofovir/ lamivudine and the multi-tablet regimen containing dolutegravir and tenofovir/ lamivudine were high, with no significant difference between groups. Factors consistently associated with lower HRQoL were being single (unmarried), having a lower educational level, recent cigarette smoking, recent signs and symptoms of anxiety or depression, comorbid disease and the occurrence of adverse drug reactions. We observed high levels of HRQoL in cART-treated people and no differences between dolutegravir and efavirenz-based regimens. This study provides inputs to future economic analysis and identifies opportunities to increase the HRQoL of patients by targeting modifiable factors.
Identifiants
pubmed: 30727749
doi: 10.1080/09540121.2019.1576841
doi:
Substances chimiques
Alkynes
0
Benzoxazines
0
Cyclopropanes
0
Drug Combinations
0
Heterocyclic Compounds, 3-Ring
0
Oxazines
0
Piperazines
0
Pyridones
0
Tablets
0
dolutegravir
DKO1W9H7M1
efavirenz
JE6H2O27P8
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM